Importantly, recent developed BAP1 inhibitor iBAP-II could significantly reduce the small cell lung cancer (SCLC) cell viability and suppress tumor growth in vivo which proved an evidence for the oncogenic function of BAP1 and blocking BAP1 activity could be a novel therapeutic strategy [45]. The gene discussed is BAP1; the disease is small cell lung carcinoma.